Five stocks drop sharply on Oct 6, led by ArriVent BioPharma after lung cancer drug trial failure.

On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition Corp. II fell 50.1% amid volatility ahead of its merger with Evernorth, which is expected to close on October 7. Twist Bioscience and 10x Genomics also declined amid a broader selloff in genomics and testing stocks. WISeSat.Space Holdings reversed some gains with a 23.7% drop, though no specific news explained its decline. These movements highlight sector-specific challenges and merger-related volatility.

Twist Bioscience is trading at USD 167.59 with a 1-day decline of 18.25% on Pluang as of Oct 07, 2026 04:23 WIB, reflecting ongoing pressure in the genomics sector. Similarly, 10X Genomics shares are down 17.49% at USD 80.65, showing continued volatility in health-related stocks. These figures align with the broader selloff noted in the article, highlighting sector-specific challenges and merger-related uncertainty.